Search Results

Russia's MEPhI Receives Over 1 Billion Rubles in Funding for Two Domestic Scientific Instrument Projects

The Russian Ministry of Science and Higher Education will allocate 2.81 billion rubles to support the development of eight types of domestically produced scientific research equipment. According to the results of an additional competitive selection, the funds are planned to be disbursed from 2026 to 2028, with six universities and research institutions set to receive support. Among them, the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute) will receive the largest share, with two projects totaling slightly over 1 billion rubles in funding. Under the arrangement, MEPhI will receive 591 million rubles for the development of a tandem quadrupole time-of-flight mass spectrometer (QTOF MS), and an additional 433 million rubles for the atom probe tomography project. Both projects have previously been approved by the Russian Academy of Sciences and included in...

2026-08-12

Korea's Naju Artificial Sun Research Facility Expected to Receive Preliminary Feasibility Study Results in September

The project to build the Naju Artificial Sun research facility in Korea is expected to receive the results of the national preliminary feasibility study in September. With a total investment of approximately 1.2 trillion KRW, the project plans to construct large-scale nuclear fusion research and demonstration infrastructure in Wangok-myeon, Naju City, South Jeolla Province, and is regarded by local governments as a key pillar in the future industrial layout of the South Jeolla–Gwangju Integrated Special Zone. The Ministry of Science and ICT (MSIT) designated the "Nuclear Fusion Core Technology Development and Strategic Infrastructure Construction Project" as a national R&D project and included it in the preliminary feasibility study on January 30. According to the previous schedule, the evaluation period was approximately seven months. The results were originally expected to be announced in August, but...

2026-08-11

Morehead State University Receives $50,000 Grant to Support Nuclear Medicine Technology Bachelor's Program

Morehead State University in the United States recently received a $50,000 grant to strengthen its Bachelor of Science in Nuclear Medicine Technology program, supporting the university's efforts to train medical imaging professionals for Kentucky's healthcare system. The funding was provided by the Kentucky Board of Medical Imaging and Radiation Therapy and administered by the Kentucky Council on Postsecondary Education. The project funds were awarded through a competitive bidding process, with a focus on supporting nuclear medicine technology education programs in Kentucky, aiming to increase the number of qualified professionals entering the state's healthcare industry. The newly established nuclear medicine technology undergraduate program under Morehead State University's Department of Imaging Sciences will prepare students in the field of medical imaging...

2026-08-11

ITM Receives Complete Response Letter from FDA for ¹⁷⁷Lu-edotreotide New Drug Application

Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE (ITM) announced on August 10 that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 7, 2026, regarding the New Drug Application (NDA) for its investigational drug ¹⁷⁷Lu-edotreotide (ITM-11). The drug is intended for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2026-08-11

Former U.S. President Biden's Prostate Cancer Progress: Has Received Radiation Therapy and Hormone Therapy

The health condition of former U.S. President Joe Biden has recently drawn renewed attention. In an interview video, his son Hunter Biden stated that after Biden was diagnosed with prostate cancer, the cancer cells had metastasized, spreading to the bones and other parts of the body, and described the process as extremely painful. According to relevant information, Biden, now 83 years old, disclosed in May 2025 that he had been diagnosed with an aggressive form of prostate cancer, with cancer cells confirmed to have spread to the bones at that time. In October, a Biden spokesperson announced that he was undergoing radiation therapy and hormone therapy. Radiation therapy is one of the common nuclear technology medical applications in tumor treatment, primarily using ionizing radiation on tumor tissue to...

2026-08-10

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

Ukraine's Radon Association Receives EU-Assisted Equipment to Enhance Operational Reliability of IASRM Radiation Monitoring System

On August 4, 2026, the Ukrainian state non-profit company Radon Association received five modern support systems to enhance the uninterrupted operation capability of the Integrated Automated Radiation Monitoring System (IASRM). The project is financially supported by the European Union through the Science and Technology Center in Ukraine, pursuant to Agreement No. INSC/2023/442-610 signed on May 22, 2023. Under the contractual arrangements, the relevant equipment has been delivered to the regional branches of the Radon Association and the central production base branch, with installation completed at the designated facilities. The systems installed this time mainly include backup power supply equipment such as diesel generators, which can provide continuous power to IASRM equipment during main power interruptions or shutdowns, thereby ensuring the normal operation of the radiation monitoring system under abnormal power supply conditions.

2026-08-10

DNT "Radon Association" Receives EU Technical Assistance Equipment to Strengthen Radiation Dose Monitoring Capabilities

On August 4, 2026, under the framework of the EU International Technical Assistance Project, the DNT Radon Association received a batch of modern measurement equipment for radiation dose monitoring, aimed at enhancing radiation monitoring and dose control capabilities. The project is financially supported by the EU through the Science and Technology Center in Ukraine, pursuant to Donor Agreement No. 700001998 signed on June 24, 2024. In accordance with the contractual arrangements, the relevant measurement equipment has been delivered to the Association's interregional branches and central production base branches. Following delivery, the DNT Radon Association conducted acceptance testing of the supplied measurement equipment. The test results demonstrated that the equipment meets the requirements for its intended use. Concurrently, the Association also organized relevant personnel to undergo training in equipment operation and maintenance; upon completion of the training and knowledge assessment, the relevant experts were awarded certificates of completion.

2026-08-10

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Mutsu City in Japan agrees to study receiving fuel from other companies at interim spent fuel storage facility

On August 7, Mutsu City in Aomori Prefecture, Japan, notified Tokyo Electric Power Company Holdings (TEPCO Holdings) and Japan Atomic Power Company (JAPC) that it agreed to allow the two companies to study a plan to receive spent nuclear fuel from other electric power companies at the local interim spent fuel storage facility. The facility, promoted and constructed by entities related to the two companies, is the only facility in Japan located outside nuclear power plant sites for interim storage of spent nuclear fuel. Under the current arrangement, the facility only accepts spent nuclear fuel from TEPCO Holdings and JAPC, and spent nuclear fuel from other companies is not permitted to be transported in. On the same day, Mutsu City Mayor Tomoya Yamamoto met with senior executives of the two companies at City Hall...

2026-08-07

KHNP's "Integrated Nuclear Power Plant Maintenance Personnel Qualification System" Receives Official Government Recognition

On August 7, Korea Hydro & Nuclear Power (KHNP) announced that its integrated nuclear power plant maintenance personnel qualification system has officially received government recognition from the Korea Human Resource Development Service for Emerging Industries, an affiliate of the Ministry of Employment and Labor. This recognition signifies that the qualification system, used internally by the company to enhance employee job competencies, has received official confirmation in terms of evaluation standards, operational frameworks, and management mechanisms, providing a more credible institutional foundation for nuclear power plant equipment operation and maintenance capability building. The core of this recognized system lies in integrating the qualification frameworks previously operated separately by various nuclear maintenance partner companies into unified standards. This marks the first time such a standardized model has been established in Korea's nuclear maintenance sector...

2026-08-07

University of Kansas Receives DOE Funding to Build New-Generation Detectors for CERN's Large Hadron Collider

A particle detector development project led by the University of Kansas has recently received funding from the U.S. Department of Energy's Established Program to Stimulate Competitive Research (DOE EPSCoR). The project, funded at $1 million, will be used to design and build two High-Luminosity Zero Degree Calorimeters (HL-ZDC) for the Compact Muon Solenoid experiment (CMS) at CERN's Large Hadron Collider (LHC). The four-year project is co-led by Michael Murray, professor in the Department of Physics and Astronomy at the University of Kansas, and Christophe Royon, distinguished professor at the University of Kansas. Murray also serves as the project lead for the CMS High-Luminosity Zero Degree Calorimeter upgrade...

2026-08-06

First American Nuclear Company (FANCO) Receives DOE Funding to Accelerate Advanced Nuclear Reactor Development

First American Nuclear Company (FANCO) has received two Rapid Turnaround Experiment (RTE) awards from the U.S. Department of Energy's Office of Nuclear Energy, enabling the company to leverage specialized national laboratory research capabilities to support the development of its EAGL-1 small modular reactor. These awards were granted during the FY2026 RTE selection cycle, which evaluates proposals based on technical superiority, feasibility, and relevance to DOE's nuclear energy programs. The program provides researchers with free access to radiation testing, post-irradiation examination facilities, and technical expertise. FANCO-approved research projects include a study on the effects of extrusion temperature on FeCrAl-ODS alloys in liquid metal fast...

2026-08-06

Zhangzhou Energy Chemistry Laboratory Receives CNAS Accreditation

Recently, the Zhangzhou Energy Chemistry Laboratory received the laboratory accreditation certificate issued by the China National Accreditation Service for Conformity Assessment (CNAS). CNAS is the national accreditation body designated by the State Administration for Market Regulation in accordance with the Regulations of the People's Republic of China on Certification and Accreditation and the Measures for the Supervision and Administration of Accreditation Bodies, and its accreditation results can achieve international mutual recognition under the Mutual Recognition Arrangement of the International Accreditation Forum. The company's chemistry laboratory strictly benchmarked against CNAS-CL01:2018 "Accreditation Criteria for the Competence of Testing and Calibration Laboratories," and solidly advanced various foundational tasks including the preparation of system documents, implementation of quality control, enhancement of personnel skills, and metrological traceability of equipment. After trial operation, internal audit...

2026-08-04

Huaneng Nuclear Power Receives First WANO Corporate Peer Review

From July 14 to 24, 2026, Huaneng Nuclear Power received its first Corporate Peer Review (CPR) organized by the Atlanta Center of the World Association of Nuclear Operators (WANO), successfully achieving the set objectives. WANO CPR is a widely accepted headquarters-level peer review in the global nuclear industry and serves as an important channel for in-depth international exchange. A 14-member assessment team, consisting of 7 foreign experts from the United States and Canada, along with personnel from the WANO Shanghai Office and industry management, conducted the review in accordance with WANO peer review standards. The evaluation covered seven areas: corporate leadership, corporate governance, oversight and monitoring, independent oversight, corporate support services, human resources and leadership development, and...

2026-07-31